Farmagens Health Care

Farmagens Health Care is a leading Italian company specializing in biotechnology research for Chronic Non-Communicable Diseases (NCDs) and in the research and development of innovative therapies, offering effective, safe, and personalized treatments in line with the principles of modern Precision Medicine. In 2016, Farmagens Health Care became the first company in the world to patent a signal molecule and transcription factor capable of positively influencing the homeostasis of the immune system, as well as biosynthesizing cannabinoids and other endogenous molecules. This breakthrough marked a significant milestone in biotechnology research within the sector.

This pioneering achievement serves as the foundation for the sustainable production of bioactive compounds, attracting global scientific interest. Farmagens Health Care’s current mission is to strengthen its leadership role and contribute to the advancement of Precision Medicine, expanding the therapeutic potential of Endogenous Biomolecules and endocannabinoids. The company is committed to promoting the Italian “Made in Italy” brand in scientific research.

At the “Rita Levi Montalcini Biotech Forum in Doha” on April 16-17, our goal is to seek international partnerships for the development of biotech research projects focused on therapeutic ALIAMIDES and other new Endogenous Molecules. The Farmagens delegation at the Forum will include CEO Augusto Sannetti, R&D team members Irene Palenca and Sara Rurgo, as well as Davide Della Morte Canosci, the Italian Society of Precision Medicine’s (S.I.E.M.PRE) expert from the University of Tor Vergata in Rome, who is also a Counselor to the Italian Minister of Health and the Minister of Scientific Research.

Farmagens Health Care’s objective at the Biotech Forum in Doha is to explore potential scientific collaborations in innovative therapies for metabolic and inflammatory diseases related to aging, with particular focus on pre-clinical and clinical research, and the industrial development of new therapeutic approaches for Non-Communicable Chronic Diseases (NCDs) With its expertise in Pharmacogenomics and Nutrigenomics, Farmagens Health Care possesses the most advanced knowledge in Europe on the Human Microbiome, thanks to proprietary studies, diagnostic methods, and patented biotechnological skills derived from next-generation sequencing (NGS) technology.

These advancements are carried out in collaboration with the associated laboratory “GENOMICA – Next Generation Genetics,” an advanced scientific unit of the Human Microbiome Care Research Institute (Clinical Advancement in Research and Education), an Italian Scientific Authority of the Italian Society of Precision Medicine (S.I.E.M.PRE). The “Human Microbiome” is a crucial endocrine organ that influences immune system function. Alterations in the microbiome increase the risk of developing various diseases.

Farmagens Health Care continues the research and development work initiated thirty years ago by Rita Levi Montalcini, the Italian Nobel Laureate in Medicine and Neuro-Science, who was the first to recognize the importance of lipid-based Endogenous Biomolecules involved in therapeutic pleiotropic activities. The Montalcini Global Biotech Forum in Doha presents an excellent opportunity to engage with public and private companies, learn about partnership opportunities, and explore collaboration with startups or research institutions involved in economic, commercial, and industrial exchanges with Farmagens Health Care.

Farmagens Health Care is Italy’s leading company in the research and development of innovative therapies represented by new Endogenous Biomolecules, which are the frontier of Biotechnology in the Medical sector. These therapies offer pharmaceutical companies, entrepreneurs, and investors opportunities for the production of endocannabinoid molecules and other Endogenous Biomolecules. These advances are highly competitive in terms of green sustainability, making the sector and entrepreneurial proposals particularly attractive for “Venture Capital” or “Private Equity Funds.”